Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat.
Pineal melatonin secretion declines with aging, whereas visceral fat, plasma insulin, and plasma leptin tend to increase. We have previously demonstrated that daily melatonin administration at middle age suppressed male rat intraabdominal visceral fat, plasma leptin, and plasma insulin to youthful levels; the current study was designed to begin investigating mechanisms that mediate these responses. Melatonin (0.4 microg/ml) or vehicle was administered in the drinking water of 10-month-old male Sprague Dawley rats (18/treatment) for 12 weeks. Half (9/treatment) were then killed, and the other half were submitted to cross-over treatment for an additional 12 weeks. Twelve weeks of melatonin treatment decreased (P<0.05) body weight (BW; by 7% relative to controls), relative intraabdominal adiposity (by 16%), plasma leptin (by 33%), and plasma insulin (by 25%) while increasing (P<0.05) locomotor activity (by 19%), core body temperature (by 0.5 C), and morning plasma corticosterone (by 154%), restoring each of these parameters toward more youthful levels. Food intake and total body fat were not changed by melatonin treatment. Melatonin-treated rats that were then crossed over to control treatment for a further 12 weeks gained BW, whereas control rats that were crossed to melatonin treatment lost BW, but food intake did not change in either group. Feed efficiency (grams of BW change per g cumulative food intake), a measure of metabolic function, was negative in melatonin-treated rats and positive in control rats before cross-over (P<0.001); this relationship was reversed after cross-over (P<0.001). Thus, melatonin treatment in middle age decreased BW, intraabdominal adiposity, plasma insulin, and plasma leptin, without altering food intake or total adiposity. These results suggest that the decrease in endogenous melatonin with aging may alter metabolism and physical activity, resulting in increased BW, visceral adiposity, and associated detrimental metabolic consequences.
Wolden-Hanson
T
T
Veterans Administration Puget Sound Health Care System and University of Washington, Seattle 98195, USA.
Mitton
D R
DR
McCants
R L
RL
Yellon
S M
SM
Wilkinson
C W
CW
Matsumoto
A M
AM
Rasmussen
D D
DD
D000005:Abdomen; D015502:Absorptiometry, Photon; D000273:Adipose Tissue / Q000033:anatomy & histology / Q000187:drug effects*; D000284:Administration, Oral; D000311:Adrenal Glands / Q000187:drug effects; D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects / Q000502:physiology*; D001831:Body Temperature / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects* / Q000502:physiology; D002755:Choice Behavior; D004327:Drinking Behavior / Q000187:drug effects / Q000502:physiology; D004334:Drug Administration Schedule; D002149:Energy Intake / Q000187:drug effects* / Q000502:physiology; D007328:Insulin / Q000097:blood / Q000502:physiology*; D020738:Leptin / Q000097:blood*; D008297:Male; D008550:Melatonin / Q000008:administration & dosage / Q000494:pharmacology*; D009043:Motor Activity / Q000187:drug effects; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D012439:Saccharin; D013649:Taste; D013950:Thymus Gland / Q000187:drug effects
D007328:Insulin; D020738:Leptin; D012439:Saccharin; D008550:Melatonin